Clinical Trials Logo

Filter by:
NCT ID: NCT05433376 Active, not recruiting - Clinical trials for Coronary Artery Disease

SOLSTICE Trial in China

Start date: April 15, 2021
Phase: N/A
Study type: Interventional

This is a small sample size clinical trial in Chinese population to assess the safety and effectiveness of the Shockwave Coronary Intravascular Lithotripsy (IVL) System to treat de novo, calcified, stenotic, coronary lesions prior to stenting.

NCT ID: NCT05433259 Active, not recruiting - Contact Lenses Clinical Trials

Biometric Factors Changes Caused by Myopia Orthokeratology (OK) Lens

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

Subjects fit with VST or CRT type lens are reviewed 1 day to 2 year after first wearing the lens. Ocular examinations were performed, including slit-lamp biomicroscope, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), corneal topography (Medmont E300W, Medmont Pty Ltd, Melbourne, Australia), corneal refractive power (autorefractometer, KR880, Topcon, JAPAN), corneal epithelial thickness (Optical Coherence Tomography, RTVue-XR), axial length using IOL-Master 700 (Carl Zeiss Meditec AG). To investigate corneal and retina changes caused by overnight OK lens.

NCT ID: NCT05432544 Active, not recruiting - Hyperlipemia Clinical Trials

Safety and Tolerability of SHR-1918 in Healthy Subjects

Start date: June 27, 2022
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of SHR-1918 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-1918 injection in healthy subjects.

NCT ID: NCT05431803 Active, not recruiting - Acromegaly Clinical Trials

Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

Start date: June 30, 2022
Phase:
Study type: Observational

This study aims to assess the one-year effectiveness and safety of LAN among patients with acromegaly in China in routine clinical practice. In addition, the study is designed to understand the real-world treatment patterns and outcomes of LAN among Chinese patients with acromegaly.

NCT ID: NCT05430451 Active, not recruiting - Smoking Cessation Clinical Trials

Simple Physical Exercise With Instant Messaging Support for Smoking Via "Quit to Win" Contest 2022 (QTW2022)

Start date: June 18, 2022
Phase: N/A
Study type: Interventional

This project aims to test the effectiveness of an integrated intervention of brief cessation advice (AWARD) and simple physical exercise with Instant Messaging (IM) support compared with control participants among current smokers who joined the contest.

NCT ID: NCT05428657 Active, not recruiting - Clinical trials for Neurodevelopmental Disorders

EC Brain Program for Children With Special Education Needs

Start date: October 19, 2020
Phase: N/A
Study type: Interventional

Children with special education needs (SEN) (e.g., autism, attention-deficit/hyperactivity disorder, dyslexia) who are studying in the mainstream primary schools are commonly found to have difficulties in learning school materials, and controlling their emotion and behaviors in class. Such schooling problems are likely related to their deficient attention, self-control ability and language abilities. As a result, they will easily be stressful, losing confidence, or even be the target of bullying or discrimination. This project aims to evaluate a neuroscience based after-school training program, namely EC Brain Program, to improve academic performance, cognition (attention, self-control and language ability), behaviors and psychological health of primary school students with SEN. The EC Brain Program is composed of computerized training programs that were developed to enhance abilities of attention, self-control and temporal processing (i.e., a fundamental cognitive ability in mastering reading and language skills), and education on basic neuroscience knowledge and ways to enhance brain functions and psychological wellness, e.g., relaxation, stress management and balanced healthy diet. A total of 100 - 250 students with SEN from 10 ordinary primary schools will be recruited in 3-year period. They will be randomly assigned into two groups. Both groups will undergo pre- and post-assessments evaluating their academic performance, cognitive functions, saccadic eye movements, physical and mental health conditions before and after the training. Students in the group A will have to participate in the EC Brain after-school program, whereas students in the group B will join conventional intervention. It is an eight-month weekly program, 90 minutes per session. It is hypothesized that students who have joined the EC Brain Program will show greater extent of improvement in academic performance, behavioral problems, cognitive functions (e.g., attention, learning, self-control, language), saccadic eye movements and psychological wellness than those in the other group. The findings of present study will shed some light on the effectiveness and applicability of the EC Brain Program as a potential after-school neuropsychological intervention for students with SEN.

NCT ID: NCT05426486 Active, not recruiting - Clinical trials for HER2-positive Breast Cancer

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Start date: May 23, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, open label Phase II-III neoadjuvant study comparing the efficacy and safety of ARX788 combined with pyrotinib maleate versus TCBHP (trastuzumab plus pertuzumab with docetaxel and carboplatin) in patients with HER2-positive breast cancer.

NCT ID: NCT05420402 Active, not recruiting - Surgery Clinical Trials

Effect of Different Administrations of Propofol on Emergence Agitation in Preschool Children Undergoing Ambulatory Surgery

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

This study evaluates the influence of different dose and methods of propofol on emergence agitation(EA) through a randomized controlled trial when preschool children undergoing ambulatory surgery of inguinal hernia.

NCT ID: NCT05415345 Active, not recruiting - Clinical trials for Human Papilloma Virus Infection Type 16

Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin

Start date: October 25, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and safety of co-immunization with recombinant human papillomavirus bivalent (Types 16,18) vaccine (Escherichia coli) and Hepatitis E vaccine (Escherichia coli)

NCT ID: NCT05414201 Active, not recruiting - Clinical trials for Non-infectious Intermediate Posterior- or Pan-uveitis

A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis

Start date: July 7, 2022
Phase: Phase 4
Study type: Interventional

Non-infectious intermediate-, posterior- and pan-uveitis (NIIPPU) are sight threatening diseases with a high patient burden and negative impact on quality of life. Corticosteroids remain the mainstay of first-line treatment for NIIPPU in China despite serious side effects associated with long-term and high-dose corticosteroid use. Adalimumab is used to treat NIIPPU in adults who have had inadequate response to corticosteroids, or who need corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. The purpose of this study is to assess adverse events and effectiveness of adalimumab in Chinese participants requiring high dose corticosteroids with NIIPPU. Adalimumab is a conditionally approved drug in China used to treat participants with NIIPPU. All participants will receive the same treatment. Approximately 87 adult participants will be enrolled at approximately 15 sites in China. Participants will receive one subcutaneous loading dose of adalimumab at baseline followed a week later by a lower dose of adalimumab every other week for up to 30 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.